Ipilimumab + Nivolumab

Phase 2UNKNOWN

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Major Salivary Gland Carcinoma

Conditions

Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVC Major Salivary Gland Carcinoma

Trial Timeline

May 19, 2017 → Aug 11, 2025

NCT ID

NCT03146650

About Ipilimumab + Nivolumab

Ipilimumab + Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Major Salivary Gland Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03146650. Target conditions include Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05200988	Phase 2	Active	Mar 14, 2022	Sep 5, 2027	Urothelial Carcinoma
NCT04933903	Phase 2	Recruiting	Oct 5, 2021	Apr 1, 2026	Non Small Cell Lung Cancer
NCT04969887	Phase 2	Active	Aug 3, 2021	Mar 1, 2027	Advanced Biliary Tract Cancer
NCT04463368	Phase 1	Completed	Mar 8, 2021	Jul 26, 2024	Uveal Melanoma
NCT04717154	Phase 2	Completed	Jan 19, 2021	Dec 18, 2025	Prostatic Neoplasms, Castration-Resistant
NCT04124601	Phase 2	Completed	Jun 1, 2020	Mar 15, 2024	Rectal Cancer
NCT04118166	Phase 2	Completed	Oct 1, 2019	Apr 26, 2022	Soft Tissue Sarcoma
NCT03340129	Phase 2	Recruiting	Aug 14, 2019	Aug 1, 2029	Melanoma Stage Iv
NCT03682276	Phase 1/2	UNKNOWN	Mar 1, 2019	Dec 1, 2023	Hepatocellular Carcinoma
NCT03305445	Phase 1	Completed	May 14, 2018	Apr 1, 2021	Relapsed Diffuse Large B-Cell Lymphoma
NCT03425331	Phase 2	Terminated	Apr 10, 2018	Nov 28, 2021	Non-small Cell Lung Cancer
NCT03387761	Phase 1	Completed	Jan 15, 2018	Jan 7, 2025	Urothelial Carcinoma
NCT03333616	Phase 2	Active	Dec 28, 2017	Dec 31, 2026	Genitourinary Cancer
NCT03203473	Phase 2	Active	Oct 26, 2017	Jun 28, 2026	Renal Cancer
NCT03168464	Phase 1/2	Terminated	Oct 9, 2017	Mar 11, 2022	Non Small Cell Lung Cancer Metastatic
NCT02892734	Phase 2	Terminated	Sep 18, 2017	Feb 4, 2019	HER2/Neu Negative
NCT02923934	Phase 2	Completed	Aug 22, 2017	Dec 12, 2023	Gastrointestinal Cancer
NCT03146650	Phase 2	UNKNOWN	May 19, 2017	Aug 11, 2025	Major Salivary Gland Carcinoma
NCT03122522	Phase 2	Active	Apr 17, 2017	Apr 1, 2026	Metastatic Melanoma
NCT03043599	Phase 1/2	Completed	Feb 13, 2017	Nov 16, 2023	Small Cell Lung Cancer

Competing Products

20 competing products in Major Salivary Gland Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Duloxetine Hydrochloride	Eli Lilly	Pre-clinical	23
LY2216684	Eli Lilly	Phase 1	33
LY2216684	Eli Lilly	Phase 1	33
Duloxetine	Eli Lilly	Phase 3	77
LY2216684 + Digoxin	Eli Lilly	Phase 1	33
Duloxetine + Paroxetine	Eli Lilly	Phase 3	77
Duloxetine + placebo	Eli Lilly	Phase 3	77
LY2216684 + Placebo + Escitalopram	Eli Lilly	Phase 2	52
FK949E	Astellas Pharma	Phase 1	33
quetiapine extended release (XR) + Placebo	Astellas Pharma	Phase 2	52
FK949E	Astellas Pharma	Phase 1	33
FK949E	Astellas Pharma	Phase 1	33
FK949E	Astellas Pharma	Phase 1	33
Mirtazapine Tablets	Sun Pharmaceutical	Approved	85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1	Ono Pharmaceutical	Phase 2	52
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	52
Pramipexole ER + Escitalopram	Cipla	Phase 2	52
LY2216684 + Sertraline	Eli Lilly	Phase 1	33
LY2216684 + Placebo + Lorazepam	Eli Lilly	Phase 1	33
LY2216684 + SSRI	Eli Lilly	Phase 3	77

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved